ArteraAI IPO

Artera was founded in 2021 by Andre Esteva. The company has not publicly endorsed plans to participate in an IPO.

Artera is the developer of AI-powered predictive and prognostic cancer tests. The company's flagship product, the ArteraAI Prostate test, aims to predict the benefits of therapy for patients with localized prostate cancer. As of the public launch in March 2023, Artera had raised $90 million in venture capital funding from investors including Coatue, Johnson & Johnson Innovation, Koch Disruptive Technologies, Walden Catalyst Ventures, TIME Ventures, Breyer Capital, and Marc Benioff. Artera did not disclose valuation figures at the time of launch.

These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO.

Buy or sell ArteraAI stock Learn more about ArteraAI stock

Learn more about ArteraAI

Is ArteraAI a publicly traded company?

ArteraAI is a private company and not publicly traded.

If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.

Will ArteraAI go IPO?

ArteraAI has not yet filed for an IPO. However, it's important to note that IPOs are not the sole avenue for a private company to transition to public trading. Private companies can also go public through alternative methods such as but limited to Special Purpose Acquisition Companies (SPACs), direct listings, or through mergers and acquisitions. Find out which companies are eyeing an IPO on our Tech IPO Calendar 2024.

What is ArteraAI's IPO price?

The IPO price for ArteraAI will be known only if it becomes public. However, you may access the "Price At Last Round" and the "Implied EV" for publicly traded comparable companies with Forge Data.

Can you invest in ArteraAI pre-IPO?

ArteraAI is privately held company and is not publicly traded, therefor investing in ArteraAI pre-IPO is only available to accredited investors. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to invest in private companies before their potential IPO. If you are not an accredited investor, discover how to begin the the process to potentially qualify for new investment opportunities.

What is the value of my ArteraAI shares?

To determine the value of your ArteraAI shares, create a free account to gain access to Forge’s platform. Forge Markets contains pricing information for hundreds of pre-IPO companies. A Private Market Specialist will also be available to assist you with any inquiries related to your ArteraAI shares. You can also learn more about how to sell your private shares before getting started.

Can you sell ArteraAI before it goes public?

Yes, you can seek to sell shares in ArteraAI while it remains private. If you are considering selling, you can register today for free to get started. Once registered, a Private Market Specialist will guide you through any questions you might have. You may also continue to browse through our resources to help you understand the implications and procedures involved in selling your private market shares.

What is ArteraAI's funding to date?

ArteraAI has raised $89.5MM to date.

When was ArteraAI founded?

ArteraAI was founded in 2021.

Who are ArteraAI's major investors?

Koch Disruptive Technologies

Coatue Management

Breyer Capital

Time Ventures

Johnson & Johnson Innovation

FactoryHQ

Walden Catalyst

ArteraAI funding rounds and last known valuation

Date	Funding Round	Funding Raised	Price per Share	Last Known Valuation
4/25/2022	Series Seed-1, Seed-2 and Seed-3	$89.5MM raised	$XXX.XX	$XXX.XX

Based on primary financings

Frequently Asked Questions

Updated on: Jul 26, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.